title: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.
abstract: BACKGROUND
  The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC). Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLC patients. Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded. IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections.
  
  
  RESULTS
  A positive IGF1R expression (score > or = 100) was observed in 282 cases (76.4%) and was significantly associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02). No difference in survival was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used (45 versus 55 months, P = 0.36). No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status.
  
  
  CONCLUSIONS
  IGF1R expression does not represent a prognostic factor in resected NSCLC patients. Patients with squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the different sensitivity to anti-IGF1R agents observed in clinical trials.
authors.affiliation: Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano. Electronic address: federico.cappuzzo@humanitas.it.
authors.forename: F
authors.initials: F
authors.lastname: Cappuzzo
authors.affiliation: Department of Pathology, Ospedale Bellaria, Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Tallini
authors.affiliation: Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
authors.forename: G
authors.initials: G
authors.lastname: Finocchiaro
authors.affiliation: University of Colorado Cancer Center, Aurora, CO, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Wilson
authors.affiliation: Department of Pathology, Ospedale Bellaria, Bologna, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Ligorio
authors.affiliation: Statitistic Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Giordano
authors.affiliation: Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
authors.forename: L
authors.initials: L
authors.lastname: Toschi
authors.affiliation: Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
authors.forename: M
authors.initials: M
authors.lastname: Incarbone
authors.affiliation: Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
authors.forename: R
authors.initials: R
authors.lastname: Cavina
authors.affiliation: Division of Molecular Pathology, University Hospital, Basel, Switzerland.
authors.forename: L
authors.initials: L
authors.lastname: Terracciano
authors.affiliation: Department of Pathology, University of Milan School of Medicine, Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Roncalli
authors.affiliation: Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
authors.forename: M
authors.initials: M
authors.lastname: Alloisio
authors.affiliation: University of Colorado Cancer Center, Aurora, CO, USA.
authors.forename: M
authors.initials: M
authors.lastname: Varella-Garcia
authors.affiliation: University of Colorado Cancer Center, Aurora, CO, USA.
authors.forename: W A
authors.initials: WA
authors.lastname: Franklin
authors.affiliation: Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
authors.forename: A
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D012189:Retrospective Studies; D015996:Survival Rate; D046888:Tissue Array Analysis; D016896:Treatment Outcome
chemical_list: D017526:Receptor, IGF Type 1